AnaptysBio Inc (NASDAQ:ANAB) – SunTrust Banks lowered their FY2020 earnings estimates for shares of AnaptysBio in a report issued on Sunday, June 23rd, according to Zacks Investment Research. SunTrust Banks analyst J. Lee now anticipates that the biotechnology company will earn ($4.73) per share for the year, down from their prior forecast of ($4.58). SunTrust Banks has a “Buy” rating and a $93.00 price objective on the stock.
ANAB has been the topic of a number of other reports. HC Wainwright set a $126.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a research report on Monday, June 24th. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th. Stifel Nicolaus downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating and dropped their target price for the stock from $124.00 to $74.00 in a report on Friday, June 21st. Credit Suisse Group dropped their target price on shares of from GBX 145 ($1.89) to GBX 105 ($1.37) and set a “neutral” rating on the stock in a report on Friday, June 21st. Finally, Cantor Fitzgerald raised their target price on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $111.25.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01.
Several large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in shares of AnaptysBio by 0.9% in the first quarter. FMR LLC now owns 4,047,987 shares of the biotechnology company’s stock valued at $295,705,000 after buying an additional 35,252 shares in the last quarter. BlackRock Inc. grew its stake in shares of AnaptysBio by 11.7% in the fourth quarter. BlackRock Inc. now owns 1,816,825 shares of the biotechnology company’s stock valued at $115,894,000 after buying an additional 189,685 shares in the last quarter. OppenheimerFunds Inc. grew its stake in shares of AnaptysBio by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 1,075,890 shares of the biotechnology company’s stock valued at $78,592,000 after buying an additional 3,671 shares in the last quarter. Federated Investors Inc. PA boosted its position in AnaptysBio by 5.7% during the first quarter. Federated Investors Inc. PA now owns 649,620 shares of the biotechnology company’s stock worth $47,455,000 after purchasing an additional 35,000 shares during the period. Finally, Redmile Group LLC boosted its position in AnaptysBio by 36.5% during the first quarter. Redmile Group LLC now owns 496,918 shares of the biotechnology company’s stock worth $36,300,000 after purchasing an additional 132,868 shares during the period.
In related news, CEO Hamza Suria sold 22,428 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $73.76, for a total value of $1,654,289.28. Following the completion of the transaction, the chief executive officer now directly owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Marco Londei sold 10,060 shares of the firm’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total transaction of $734,983.60. Following the completion of the transaction, the insider now directly owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The disclosure for this sale can be found here. 14.00% of the stock is owned by company insiders.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
See Also: Key terms to understand channel trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.